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0. Abstract 25 
The identification of cell-free circulating mitochondrial DNA (ccf-mtDNA) in early stage 26 
Alzheimer’s disease (AD) raised the possibility that the same neurodegenerative effect could 27 
be seen in Parkinson’s disease (PD). Here and for the first time, we investigated the role of 28 
ccf-mtDNA in PD, identifying a significant reduction of ccf-mtDNA in PD patient 29 
cerebrospinal fluid (CSF) when compared to controls.  30 
Our data demonstrates that CSF ccf-mtDNA is not only a powerful biomarker for PD but, 31 
given that the effect is also seen in AD, is likely a biomarker for neurodegeneration.  32 
 33 
1. Introduction 34 
The identification of early clinical biomarkers of Parkinson’s disease (PD) is increasingly 35 
important to developing neuroprotective strategies in a rapidly ageing population. Currently, 36 
the typical clinical diagnosis of PD is based on the observation of several cardinal indicators, 37 
including tremor, bradykinesia, rigidity and postural instability,[1] however pathological 38 
process leading to PD can begin decades before these symptoms develop. Advances in 39 
imaging technologies and diagnostic algorithms are helping, but translating into 40 
understanding neurodegenerative predisposition is critical in efficient early detection and 41 
differential diagnosis. 42 
The links between mitochondria and the pathoetiology of PD are well studied, beginning in 43 
the 1970s when the potent respiratory chain inhibitor MPTP was shown to cause 44 
parkinsonism in illicit drug users,[2] through the identification of complex-I mediated 45 
reactive oxygen species formation in PD brains [3] and continuing recently, where inherited 46 
mitochondrial DNA (mtDNA) variants have been shown to affect PD risk.[4] 47 
The role of circulating cell-free (ccf) mtDNA in plasma, has been used to discriminate 48 
between breast tumor cases and controls [5] and recent work indicates that ccf-mtDNA levels 49 
increase in response to injury related immune activation.[6] Moreover, cerebrospinal fluid 50 
(CSF) investigations in pre-clinical Alzheimer’s disease (AD) patients indicate that ccf-51 
mtDNA levels are decreased when compared to matched controls, suggesting that a reduction 52 
in ccf-mtDNA may be a biomarker for early stage neurodegenerative disease.[7] Given the 53 
pathological similarities between PD and AD (neuronal cell death), we hypothesized that ccf-54 
mtDNA could also be an early indicator of PD pathology. 55 
 56 
2. Materials and Methods  57 
Subjects: 56 CSF samples, from a UK community-based PD study (males=34 and 58 
females=19, mean ages=66.5 StDev=10.5 and =62.7 StDev=7.8 years respectively), [8] were 59 
selected alongside 10 age-matched asymptomatic UK control CSF samples (males=6 and 60 
females=4, mean ages=61.2 StDev=7.6 and =60.1 StDev=2.7 years respectively). All PD 61 
cases were assessed locally by a neurologist using UK-PD Society brain bank criteria for the 62 
diagnosis of PD.[9] Disease duration < 1 year (disease duration mean=5.4 months, StDev=4.9 63 
months). 64 
At baseline, all PD cases underwent cognitive assessment; global cognitive function was 65 
assessed using the mini-mental state examination (MMSE)[10] and the Montreal Cognitive 66 
Assessment (MoCA).[11] Attention was measured using Cognitive Drug Research (CDR, 67 
Goring-on-Thames, UK) computer testing.[12] Memory was assessed using Pattern 68 
Recognition Memory (PRM) and Spatial Recognition Memory (SRM) from the computerized 69 
Cambridge Neuropsychological Test Automated Battery (CANTAB) battery.[8, 13] Mild 70 
cognitive impairment (MCI) was determined using published criteria (using 1.5 SD as a cut-71 
off).[8] Testing was repeated after 18 months.  72 
Additionally, samples were genotyped for variants known to affective cognitive function: 73 
rs9468 (defining H1/H2, MAPT) and rs429358/rs7142 (defining APOE1-4).[14] Genotyping 74 
was performed by KASPtm genotyping (LGC, Middlesex, UK). 75 
CSF Samples: Lumbar puncture (LP) was performed on consenting PD cases (n=56) (lateral 76 
or sitting position, depending on the flexibility of the patient and presence of tremor) as part 77 
of the ICICLE-PD study,[8] within a four month period after initial cognitive assessment (t=0 78 
months) and was repeated in a subset of cases (n=30) after 18 months (t=18 months), again 79 
within a four month period of the repeat cognitive assessment. 80 
Control CSF (n=10) was taken from asymptomatic age-matched controls in the same manner. 81 
To standardise collections, all LPs were performed between 8 and 10am after an overnight 82 
fast and whilst withholding Parkinson’s mediations, as some biomarkers may be altered by 83 
circadian rhythms and by medication use.[15] Samples that were free of visual contamination 84 
by blood were centrifuged within 15 minutes of collection at 2000g at 4⁰C for 10 minutes, 85 
with the supernatant then divided into aliquots of 0.25mL and frozen at -80⁰C in labelled 86 
polypropylene cryovials which do not influence biomarker outcome.[15] CSF-tau, -87 
phosphorylated-tau and –synuclein were measured in CSF using previously published 88 
methodology.[8] 89 
mtDNA copy number determination: Quantification of mitochondrial DNA was performed 90 
in triplicate by multiplex Taqman qPCR amplification of the mitochondrial genes MTND1 91 
and MTND4 and the nuclear encoded gene B2M , using serial dilutions of cloned vectors to 92 
ensure reaction linearity and for standard curve quantification [16]. Similar to previous work, 93 
samples containing >1 copies B2M per sample (n=2) were rejected, ruling out the possibility 94 
of CSF contamination with DNA from peripheral cells [7]. mtDNA copy number is expressed 95 
copies per microliter of using both MTDN1 and MTDN4. Case and control samples were 96 
randomly assigned to each run to limit run-specific stratification. 97 
Validation of qPCR results: A random proportion (10%) of samples were replicated from 98 
source DNA, with a coefficient or repeat variance estimated as 0.35% (indicating that qPCR 99 
results are reproducible). 100 
Statistical Analysis: Data were analyzed using SPSS v22 with data appropriate tests 101 
(detailed in text). Statistical significance was set at P=<0.05. 102 
  103 
3. Results 104 
Similar to a previous study [7], we were able to detect and accurately quantify ccf-mtDNA 105 
from low volumes of prepared CSF with high, whole, mtDNA target specificity. High 106 
correlation of both opposing mtDNA regions (Figure 1) indicates that the mtDNA molecule 107 
is likely intact and comparative assessment of amplicon ratios [17] did not indicate the 108 
presence of mtDNA deletions or the presence of nDNA. 109 
 110 
Comparison of ccf-mtDNA showed a significant reduction in PD cases compared to controls, 111 
when analyzing either MTND1 (Mann-Whitney P=2.0x10-3) or MTND4 (Mann-Whitney 112 
P=1.0x10-3) copy-number (Figure 2A). This is supported by receiver operating characteristic 113 
curve analysis, which indicates that MTND1 and MTND4 calculated ccf-mtDNA are strong 114 
predictors of PD status (MTND1 P= 2x10-2 and area under curve = 0.81 and MTND4 P= 115 
1x10-2 and area under curve = 0.84), Figure 2B) [18]. Subsequent assessment of t=18 month 116 
CSF ccf-mtDNA confirmed the previous reduction in PD cases when compared to controls in 117 
both MTND1 (Mann-Whitney P=1.2x10-4) or MTND4 (Mann-Whitney P=5.9x10-4) (Figure 118 
2A), but was not significantly reduced between t=0 and t=18 months (MTND1, Mann-119 
Whitney P=2.4x10-1 and MTND4 Mann-Whitney P=5.1x10-1) in PD cases. 120 
 121 
Phenotypic analysis found no association between patient age or gender to either t=0 or t=18 122 
month ccf-mtDNA (both MTND1 or MTND4) (Table 1). In addition we found no significant 123 
correlation between PD patient ccf-mtDNA when analysed as individual cardinal 124 
measurements of cognitive function or when stratified as mild-cognitive 125 
impairment/cognitively normal (Table 1). Moreover, we found no significant association 126 
when stratifying PD cases as either ‘tremor dominant’ or ‘postural instability gait difficulty’, 127 
phenotypic sub-types (Table 1) [19]. To investigate further, we correlated ccf-mtDNA to 128 
CSF-tau, -phosphorylated tau (pTau) and -α-synuclein, but failed to find a significant 129 
correlation (Table 1). At a genetic level, we found no direct correlation between MAPT 130 
(H1/H2) or APOE (E1/2/3/4) genotypes and ccf-mtDNA (Table1). Although not significant 131 
(P=7.2x10-1) we did observe an inverse trend when correlating APOE genotype to t=0 month 132 
ccf-mtDNA, with ccf-mtDNA paradoxically increasing with APOE risk alleles. 133 
 134 
Inspection of t=0 and t=18 month ccf-mtDNA measurements showed that in some instances 135 
(>10%, n=11, 36.6%) ccf-mtDNA increased over time, although not to comparative control 136 
levels. 50% of PD cases showed a >10% decrease (n=15) and a small proportion remained 137 
static (within 10%, n=4, 13.4%). However, stratification by these three categories failed to 138 
find an association to previously defined phenotypes. 139 
 140 
4. Discussion 141 
In the only study in PD to date, our investigations indicate that circulating cell-free mtDNA 142 
(ccf-mtDNA) is associated with PD. Moreover the early-disease stage in our cohort indicates 143 
that ccf-mtDNA may be an important early biomarker for PD onset.  144 
Our results are in keeping with a similar study in Alzheimer’s disease (AD),[7] which 145 
showed strikingly similar ccf-mtDNA levels when comparing AD patients to controls, 146 
indicating that ccf-mtDNA may indeed be a marker for broad neurodegeneration. 147 
A reduction in cellular mtDNA level is a hallmark of several neurological disorders, 148 
including a PBC-copy number reduction in Huntington’s disease [20] and a reduction of 149 
mtDNA in pyramidal neurons in Alzheimer's disease hippocampi.[21] However, the exact 150 
role of reduced ccf-mtDNA is unknown. In cancer, elevated ccf-mtDNA level is thought to 151 
correlate to increased apoptosis, with high copy-number cells releasing mtDNA upon death 152 
[22]. Although cell death is a hallmark of PD, we observed paradoxically lower ccf-mtDNA 153 
in cases, suggesting that neuronal mtDNA levels in patients are compromised prior to cell 154 
death. This seem likely, as neuronal mtDNA copy number is reduced in a number of 155 
neurodegenerative diseases [23, 24] and corresponds with a reduction in cellular energy. 156 
In addition, elevated plasma ccf-mtDNA is a hallmark of ICU mortality, rising as a direct 157 
response to inflammatory stimuli, [25] and cognitive impairment is associated with elevated 158 
pro-inflammatory markers in PD CSF [26], raising the possibility that elevated ccf-mtDNA 159 
may correlate with cognitive decline. However, we found no significant association between 160 
non-motor phenotypes and CSF ccf-mtDNA. This could be a limitation of the early stage of 161 
disease in our cohort, where cognitive decline has yet to reach develop, or may indicate that 162 
rising ccf-mtDNA is a feature restricted to PD motor-phenotypes. In this regard, further 163 
studies, including longitudinal studies of PD and cognitive decline, are recommended to more 164 
fully assess this. Finally, further study as to the origin of the ccf-mtDNA is warranted. 165 
Although a neuronal origin seems probable, given the phenotypic differences we observed, it 166 
is possible the ccf-mtDNA is representative of broader neuronal loss throughout the brain.   167 
 168 
Given the severity of the reduction in CSF ccf-mtDNA in PD, and supported by both 169 
subsequent re-measurement and remarkably similar data seen in AD,[7] we conclude that ccf-170 
mtDNA is a viable biomarker for the early detection of neurodegenerative disease. 171 
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Figures 293 
 294 
Figure 1 – (A) Cartoon showing the relative position of both ccf-mtDNA real-time PCR 295 
targets (MTND1 and MTND4). (B) Correlation of MTND1 and MTND4 copy-number from 296 
PD cases and controls at t=0 months (n=64) and cases at t=18 months (n=30). 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
Figure 2 – A) Analysis of cell free circulating mtDNA (ccf-mtDNA) in CSF, analysed using 305 
two mtDNA targets: MTND1 and MTDN4 showing mean mtDNA copy number per 306 
microliter CSF (with 95% CI) for PD cases at t=0 /t=18 months (shaded) and matched 307 
controls (unshaded). Asterisks indicate statistical significance (***P=10-3 and ***P=10-4). B) 308 
Receiver operating characteristic curve analysis of MTND1 (dotted line) and MTND4 (solid 309 
line) calculated ccf-mtDNA; where area under curve (AUC) =0.81 =0.84 and P=2x10-2 310 
P=1x10-2, respectively. Dashed line indicates reference line. 311 
 312 
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 317 
 318 
Table 1  - Comparative statistical analysis of ccf-mtDNA copy-number in PD cases to (A) 319 
age, gender and age of onset, (B) assessments of cognitive function (Montreal cognitive 320 
assessment score (MoCA), the mini-mental state examination score (MMSE) the unified 321 
Parkinson's disease rating scale (UPDRS), mild cognitive impairment (MCI), cognitively 322 
normal (CN),power of attention (PoA), pattern recognition memory (PRM),spatial 323 
recognition Memory (SRM)), (C) assessments of PD/dementia markers (stratified ‘postural 324 
instability gait difficulty’/’tremor dominant’ or (PIGD v TD), CSF-total tau (CSF-ttau), CSF-325 
phosphorylated tau (CSF-ptau) and CSF alpha synuclein (CSF-α-synuclein) concentrations) and 326 
(D) MAPT and APOE genotypes.  327 
 328 
  t=0 months t=18 months 
 Variable MTND1 (P) MTND4 (P) MTND1 (P) MTND4 (P) 
(A) Age** 9.00x10-2 1.70x10-1 6.44x10-1 8.48x10-1 
 Gender* 9.00x10-1 9.11x10-1 8.17x10-1 9.26x10-1 
 Age of Onset** 1.67x10-1 2.11x10-1 3.14x10-1 3.01x10-1 
 
   
  
(B) MoCa** 2.84x10-1 3.90x10-1 4.72x10-1 4.52x10-1 
 MMSE** 2.73x10-1 3.39x10-1 8.67x10-1 9.43x10-1 
 UPDRSII (on)** 3.77x10-1 4.68x10-1 2.57x10-1 6.51x10-1 
 UPDRSIII (on)** 4.22x10-1 9.97x10-1 7.57x10-1 8.19x10-1 
 MCI v CN* 5.97x10-1 3.09x10-1 1.75x10-1 1.21x10-1 
 POA** 6.93x10-1 4.67x10-1 4.39x10-1 4.37x10-1 
 PRM** 6.98x10-1 7.77x10-1 1.77x10-1 1.18x10-1 
 SRM** 7.41x10-1 6.32x10-1 5.93x10-1 5.45x10-1 
      
(C) PIGD v TD* 8.20 x10-2 7.30x10-2 6.18x10-1 6.83x10-1 
 CSF-ttau (pg/ml)** 9.69x10-1 8.95x10-1 - - 
 CSF-ptau (pg/ml)** 5.33x10-1 8.04x10-1 - - 
 CSF-α-synuclein (pg/ml) ** 1.03x10-1 1.64x10-1 - - 
 
   
  
(D) MAPT*** 8.80x10-2 5.40x10-2 7.26x10-2 4.89x10-2 
 APOE*** 8.44x10-1 7.20x10-1 8.41x10-2 8.21x10-2 
Where * is testing by Mann-Whitney U of mtDNA copy-number versus binary variable, ** is testing by 
Spearman correlation of mtDNA copy-number versus linear variable and *** is ANOVA testing of 
mtDNA copy-number versus categorical variable. 
  329 
